Haplotypes of single cancer driver genes and their local ancestry in a highly admixed long-lived population of Northeast Brazil

• Autor(a) principal: Galisa,Steffany Larissa Galdino
• Data de Publicação: 2022
• Outros Autores: Jacob,Priscila Lima, Farias,Allysson Allan de, Lemes,Renan Barbosa, Alves,Leandro Ucela, Nóbrega,Júlia Cristina Leite, Zatz,Mayana, Santos,Silvana, Weller,Mathias
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Genetics and Molecular Biology
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572022000100104
• topic: Ancestry; admixed population; cancer driver gene; single nucleotide polymorphism (SNP); haplotype.

Abstract Admixed populations have not been examined in detail in cancer genetic studies. Here, we inferred the local ancestry of cancer-associated single nucleotide polymorphisms (SNPs) and haplotypes of a highly admixed Brazilian population. SNP array was used to genotype 73 unrelated individuals aged 80-102 years. Local ancestry inference was performed by merging genotyped regions with phase three data from the 1000 Genomes Project Consortium using RFmix. The average ancestry tract length was 9.12-81.71 megabases. Strong linkage disequilibrium was detected in 48 haplotypes containing 35 SNPs in 10 cancer driver genes. All together, 19 risk and eight protective alleles were identified in 23 out of 48 haplotypes. Homozygous individuals were mainly of European ancestry, whereas heterozygotes had at least one Native American and one African ancestry tract. Native-American ancestry for homozygous individuals with risk alleles for HNF1B, CDH1, and BRCA1 was inferred for the first time. Results indicated that analysis of SNP polymorphism in the present admixed population has a high potential to identify new ancestry-associated alleles and haplotypes that modify cancer susceptibility differentially in distinct human populations. Future case-control studies with populations with a complex history of admixture could help elucidate ancestry-associated biological differences in cancer incidence and therapeutic outcomes.